Latest Publications
Improved Pharma has Expanded their Laboratory Space to Support the Growing Business
WEST LAFAYETTE, IND. (PRWEB) APRIL 26, 2021 Improved Pharma is delighted to announce the expansion of its current laboratory to accommodate additional research capabilities. The addition of the newly acquired laboratory facility in the PurdueRead more
Improved Pharma announces recent publication on expediting preclinical formulation development of amorphous lapatinib using mini-tab formulations in pediatrics
Dr, Stephen Byrn, CSO of Improved Pharma, was a key contributor to a recent publication describing the usefulness of mini-tablets in monitoring the dose-response of lapatinib solid amorphous dispersions in juvenile pigs. Juvenile pigs have been well-establishedRead more
Improved Pharma announces new publication on amorphous dispersions
A recent collaboration with our colleagues further advances the field of X-ray pair distribution function analysis applied to the analysis of amorphous solid dispersions. In this paper, we present the results of different polymer:flubendazoleRead more
Control of Nitrosamine Impurities in Human Drugs
In February 2021, the FDA issued a guidance aimed at preventing unacceptable levels of nitrosamine impurities in pharmaceutical products. This guidance required a risk assessment to be completed by March 31, 2021. This isRead more
Recent research on bedaquiline selected for the November cover of Acta Crystallographic
Improved Pharma is pleased to announce the open-source publication of research into finding new salts of bedaquiline, an important drug for the treatment of tuberculosis. The drug is currently marketed in the US asRead more
Improved Pharma presenting at AAPS 2020 PHARMSCI 360 with Rapid Fire Presentation and Poster
WEST LAFAYETTE, IND. (PRWEB) OCTOBER 26, 2020 Interact with us via poster number 924440 and the Advances and Innovation in Formulation Development Rapid Fire session. On Wednesday October 28th, Dr. Pamela Smith, COO of ImprovedRead more